![]() |
产地 | 中国 |
品牌 | Chemstan |
货号 | LC-01 |
用途 | 中间体 |
包装规格 | 20mg |
纯度 | 98%% |
CAS编号 | 1252003-15-8 |
是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体,主打中药对照品/标准品/天然植物有效单体,小分子化合物库,药物杂质。所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务。
Fields of Application :
Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
CAS Number: | 1252003-15-8 |
Purity: | >98% |
Molecular Weight: | 335.4 |
Molecular Formula: | C20H21N3O2 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
Synonyms: | N/A |
Chemical Name: | N/A |
Storage: | 2 years -20°C powder,2 weeks 4°C in DMSO,6 months -80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all iso Forms excluding HDAC8, where it has approximately 57-fold selectivity. Tubastatin A preferentially induces α-tubulin hyperacetylation at 2.5 μM. Slight induction of histone hyperacetylation is seen For Tubastatin A at 10 μM. Tubastatin A displays dose-dependent protection against homocysteic acid-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM. Tubastatin A (10 μM) induces an increase in acetylated-α-tubulin levels and the restoration of primary cilia expression in the cholangiocarcinoma cell lines (18-fold); and the restoration of primary cilia correlated with downregulated Hedgehog (Hh) and MAPK signaling pathways, as well as decreased cell proliferation rates (in average by 50%) and invasion (by 40%). Tubastatin A shows significant inhibition of TNF-α and IL-6 in LPS stimulated human THP-1 macrophages with an IC50 of 272 nM and 712 nM. Tubastatin A inhibits nitric oxide (NO) secretion in murine Raw 264.7 macrophages dose depenndently with an IC50 of 4.2 μM.Tubastatin A reduces the growth of cholangiocarcinoma in vivo. Tubastatin A (10 mg/kg) induces a 6-fold lower mean tumor weights in syngeneic rat orthotopic model of cholangiocarcinoma, and reduction of the ratios of tumor weight to liver weight and body weight (5- and 5.6-fold, respectively), as well as a greater frequency of ciliated cholangiocytes compared with controls (29% vs 1.4%). Tubastatin A significantly decreases the amount of PCNA-positive cells in the treated tumors compared with vehicle controls (34% vs 65%). Tubastat A shows significant inhibition of paw volume at 30 mg/kg i.p. in a Freund's complete adjuvant (FCA) induced animal model of inflammation. Tubastat A (30 mg/kg i.p.) significant attenuates clinical scores (~ 70%), and IL-6 expression in paw tissues of collagen induced arthritis DBA1 mouse.For the detailed information of Tubastatin A, the solubility of Tubastatin A in water, the solubility of Tubastatin A in DMSO, the solubility of Tubastatin A in PBS buffer, the animal experiment (test) of Tubastatin A, the cell expriment (test) of Tubastatin A, the in vivo, in vitro and clinical trial test of Tubastatin A, the EC50, IC50,and Affinity of Tubastatin A.
References:
C(NO)(=O)C1=CC=C(CC2C3CCN(C)CC=3C3=C2C=CC=C3)C=C1